TriSol Medical

TriSol Medical Overview

Trisol Medical goal is to develop the best-in-class Transcatheter Tricuspid Replacement Valve, which eliminates Tricuspid Regurgitation while preserving the Right Ventricle function. Trisol Medical device concept and unique design was created out of deep understanding and knowledge of the unmet need of treating Tricuspid Valve insufficiency. Trisol device is a Transcatheter Tricuspid Valve Replacement, which is implanted easily and intuitively. Trisol valve is constructed out of nitinol frame with specially designed dome-shaped leaflet. Its unique design provides a comprehensive solution to eliminating Tricuspid Regurgitation while preserving the Right Ventricle function. Trisol Valve is suited to all severe Tricuspid Regurgitation patients.

Cumulative Funding Raised Over Time ($)

Latest News

Aug 23, 2023 · www.newswire.ca

growth-positive

Trisol announces successful implants of its Transcatheter Tricuspid Valve in the US

Trisol Medical Ltd. has successfully conducted two implants of the Trisol Transcatheter Tricuspid Valve Replacement in the United States as part of an FDA approved Early Feasibility Study. The procedures were performed at the Piedmont Heart Institute in Atlanta, Georgia and the University of Virginia Health System in Charlottesville, VA. The patients, both women suffering from severe symptomatic tricuspid regurgitation, saw significant reductions in their TR levels and were discharged from the hospital within two days of the procedure. Trisol aims to complete its EFS and initiate pivotal studies in 2024.

CustomersPartners

Oct 15, 2018 · en.globes.co.il

growth-positive

Heart valve co Trisol Medical raises $2.7m

Israeli medical start-up Trisol Medical has raised $2.7m in a funding round featuring US, Israeli and Chinese investors. Trisol, which recently graduated from the Alon MedTech Ventures incubator, is developing a heart valve that can be implanted via catheterisation. The company is targeting the tricuspid valve, which it believes could provide a solution for millions of patients worldwide suffering from substantial leaking from the tricuspid valve who are unable to undergo open heart surgery. Trisol estimates the market for tricuspid valves implanted by catheterisation at $6 billion.

Investment

Funding

Team Members

2

Employees: 11-50

Web & Social Links

Locations

HaKidma St 7, Yokne'am Illit, Israel

Photos & Videos

1 item(s)

TriSol Medical Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info